Patents by Inventor Zhixiang He
Zhixiang He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240132488Abstract: The present invention belongs to the medical field, and relates to novel ?-lactamase inhibitors, for the treatment of bacterial infections in combination with ?-lactam antibiotics, including infection caused by drug resistant organisms and especially multi-drug resistant organisms. The present invention includes compounds according to formula (I): or pharmaceutically acceptable salts thereof, wherein M and R are as defined herein.Type: ApplicationFiled: March 4, 2022Publication date: April 25, 2024Inventors: Zhixiang YANG, Haikang YANG, Jinbo JI, Lijuan ZHAI, Jian SUN, Jingwen JI, Lili HE, Dong TANG, Zafar IQBAL, Yuanbai LIU, Yangxiu MU, Xueqin MA, Jianqiang YU
-
Publication number: 20240067702Abstract: A class of lactam-modified polypeptide compounds and the use thereof in the preparation of a drug for treating related diseases.Type: ApplicationFiled: December 2, 2021Publication date: February 29, 2024Inventors: Zhixiang PAN, Zhigan JIANG, Haiying HE, Guoping HU, Jian LI, Shuhui CHEN
-
Publication number: 20230391768Abstract: The present disclosure provides compounds of Formula (I?) (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK), e.g., Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).Type: ApplicationFiled: November 7, 2019Publication date: December 7, 2023Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Tinghu Zhang, Yao Liu, Zhixiang He, Mingfeng Hao, David Weinstock, Loretta Sze-Mun Li
-
Publication number: 20230357222Abstract: Disclosed are bispecific compounds (degraders) that target cereblon (CRBN) for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds as research tools and to reduce adverse side effects associated with a cereblon targeted therapy.Type: ApplicationFiled: March 16, 2021Publication date: November 9, 2023Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, Zhixiang He, Tinghu Zhang, Chelsea Powell, Eric S. Fischer, Jonathan Bushman, Guangyan Du
-
Publication number: 20230312575Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.Type: ApplicationFiled: November 11, 2022Publication date: October 5, 2023Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
-
Publication number: 20230242534Abstract: The present disclosure provides compounds of Formula (I), (II-1), (II-2), (II-3), or (II-4). The compounds of the present disclosure may be inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). In some embodiments, the compounds disclosed herein are selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). In certain embodiments, the compounds do not bind or inhibit a 5-hydroxytryptamine (5-HT) receptor. Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds disclosed herein. In some embodiments, the compounds are useful in inhibiting the activity of a kinase, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis).Type: ApplicationFiled: July 22, 2020Publication date: August 3, 2023Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Tinghu Zhang, Nicholas Paul Kwiatkowski, Nathanael S. Gray, Zhixiang He, Yanke Liang
-
Publication number: 20230151001Abstract: The present disclosure provides compounds of Formula (I?) (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK), e.g., Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).Type: ApplicationFiled: November 7, 2019Publication date: May 18, 2023Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Tinghu Zhang, Yao Liu, Zhixiang He, Mingfeng Hao, David Weinstock, Loretta Sze-Mun Li
-
Patent number: 11530219Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.Type: GrantFiled: June 27, 2019Date of Patent: December 20, 2022Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
-
Patent number: 11505560Abstract: Disclosed are heterobifunctional compounds that effectuate selective degradation of a target protein, and which include a targeting ligand that binds a target protein and at least one other protein, a ligand that binds an E3 ubiquitin ligase or a component of E3 ubiquitin ligase, and a specificity modulating linker that links the first ligand and the second ligand. Pharmaceutical compositions containing the compounds, and methods of using and making the compounds are also disclosed.Type: GrantFiled: October 19, 2018Date of Patent: November 22, 2022Assignee: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Radoslaw P. Nowak, Eric S. Fischer, Nathanael S. Gray, Tinghu Zhang, Zhixiang He, Brian Groendyke
-
Publication number: 20220280649Abstract: Disclosed are bispecific compounds (degraders) that target CDK7 for degradation. Also disclosed are pharmaceutical compositions containing the degraders and methods of using the compounds to treat disease.Type: ApplicationFiled: August 4, 2020Publication date: September 8, 2022Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael S. Gray, Guangyan Du, Tinghu Zhang, Zhixiang He, Nicholas Kwiatkowski, Jie Jiang
-
Publication number: 20220281874Abstract: The present disclosure provides compounds of Formula (I), (II-1), (II-2), (II-3), or (II-4). The compounds of the present disclosure may be inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). In some embodiments, the compounds disclosed herein are selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). In certain embodiments, the compounds do not bind or inhibit a 5-hydroxytryptamine (5-HT) receptor. Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds disclosed herein. In some embodiments, the compounds are useful in inhibiting the activity of a kinase, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis).Type: ApplicationFiled: July 22, 2020Publication date: September 8, 2022Applicant: Dana-Farber Cancer Institure, Inc.Inventors: Tinghu Zhang, Nicholas Paul Kwiatkowski, Nathanael S. Gray, Zhixiang He, Yanke Liang
-
Patent number: 11352354Abstract: A type of substituted penta-fused hexa-heterocyclic compounds having selective inhibition for PIKfyve kinase, a pharmaceutically acceptable salt and pharmaceutically acceptable solvate thereof, a method for the preparation thereof, a pharmaceutical composition comprising the same, and use of these compounds in the manufacture of a medicament for preventing or treating a disease associated with PIKfyve in vivo, in particular in the manufacture of a medicament for preventing or treating tumor growth and metastasis.Type: GrantFiled: August 3, 2018Date of Patent: June 7, 2022Assignee: Xiamen UniversityInventors: Xianming Deng, Wei Huang, Xihuan Sun, Ting Zhang, Zhixiang He, Yan Liu, Xinrui Wu, Baoding Zhang, Xiaoyang Li, Jingfang Zhang, Yun Chen, Li Li, Qingyan Xu, Zhiyu Hu
-
Publication number: 20220127260Abstract: The present disclosure provides compounds of Formula (I?) (e.g., compounds of Formula (I)), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, cocrystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The provided compounds may be kinase (e.g., Janus kinase (JAK), e.g., Janus kinase 2 (JAK2)) inhibitors. Also provided are pharmaceutical compositions and kits including the provided compounds. Further provided are methods of using the provided compounds, pharmaceutical compositions, and kits (e.g., for treating a disease (e.g., proliferative disease) in a subject in need thereof).Type: ApplicationFiled: November 7, 2019Publication date: April 28, 2022Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Tinghu Zhang, Yao Liu, Zhixiang He, Mingfeng Hao, David Weinstock, Loretta Sze-Mun Li
-
Publication number: 20220089611Abstract: The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds of the present disclosure are inhibitors of kinases (e.g., a cyclin-dependent kinase (CDK) (e.g., CDK7)). The compounds may be selective for inhibiting the activity of a kinase (e.g., CDK7) over certain other kinases (e.g., CDK2, CDK9, CDK12). Also provided are pharmaceutical compositions, kits, methods of use, and uses that involve the compounds. The compounds may be useful in inhibiting the activity of a kinase, down-regulating the transcription of MYC or MCL-1, inhibiting the growth of a cell, inducing apoptosis of a cell, treating a disease, and/or preventing a disease (e.g., proliferative disease, cystic fibrosis).Type: ApplicationFiled: December 27, 2019Publication date: March 24, 2022Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Nathanael S. Gray, Tinghu Zhang, Nicholas Paul Kwiatkowski, Jie Jiang, Mingfeng Hao, Zhixiang He
-
Publication number: 20210300941Abstract: Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.Type: ApplicationFiled: June 27, 2019Publication date: September 30, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
-
Publication number: 20210292325Abstract: Disclosed are compounds with immunomodulatory activity, methods of making the compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat diseases or disorders characterized or mediated by dysfunctional protein activity.Type: ApplicationFiled: June 27, 2019Publication date: September 23, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
-
Publication number: 20210284624Abstract: Disclosed are immunomodulatory compounds, pharmaceutical compositions containing them, and methods of making and using the compounds to treat diseases and disorders characterized by aberrant protein activity that can be targeted by cereblon.Type: ApplicationFiled: June 27, 2019Publication date: September 16, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan, Hu Liu
-
Publication number: 20210277018Abstract: Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.Type: ApplicationFiled: June 27, 2019Publication date: September 9, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Nathanael Gray, Tinghu Zhang, Eric Fischer, Alyssa Verano, Zhixiang He, Guangyan Du, Katherine Donovan, Radoslaw Nowak, Jing Ting Christine Yuan
-
Publication number: 20210130368Abstract: Disclosed are heterobifunctional compounds that effectuate selective degradation of a target protein, and which include a targeting ligand that binds a target protein and at least one other protein, a ligand that binds an E3 ubiquitin ligase or a component of E3 ubiquitin ligase, and a specificity modulating linker that links the first ligand and the second ligand. Pharmaceutical compositions containing the compounds, and methods of using and making the compounds are also disclosed.Type: ApplicationFiled: October 19, 2018Publication date: May 6, 2021Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Radoslaw P. NOWAK, Eric S. FISCHER, Nathanael S. GRAY, Tinghu ZHANG, Zhixiang HE, Brian GROENDYKE
-
Patent number: 10975092Abstract: The present invention relates to compounds (I) capable of inhibiting the Mst1/2 protein kinase activity, a preparation method therefor, a pharmaceutical composition comprising the compounds, and uses of the compounds and the pharmaceutical composition comprising the compounds in the preparation of drugs for prompting repair and regeneration of tissues and organs, prompting stem cell proliferation and somatic cell dedifferentiation, immunosuppression, and preventing or treating diseases related to nervous disorders and local ischemia.Type: GrantFiled: March 2, 2017Date of Patent: April 13, 2021Assignee: Anhui New Star Pharmaceutical Development Co., Ltd.Inventors: Xianming Deng, Dawang Zhou, Lanfen Chen, Zhixiang He, Fuqin Fan